Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Coloplast    COLO B   DK0060448595

COLOPLAST

(COLO B)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Coloplast : continues to expand its SenSura® Mio ostomy range with the new, innovative, first-of-its-kind SenSura® Mio Convex Flip ostomy product.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/12/2019 | 08:15am EDT

Designed specifically for the outward body shapes – and the first of its kind in the ostomy market – the new SenSura® Mio Convex Flip is now available in the United States.

All bodies are different, and it is a challenge to create products to fit individual bodies. The SenSura Mio ostomy care portfolio is intended to meet the differing needs of ostomates through its BodyFit Technology®. Flat and convex barriers are common, which the SenSura Mio offers a solution for.

SenSura Mio Convex Flip is a new solution for people with an outward body profile and is the first ostomy appliance designed specifically for those that are overweight, obese, or have parastomal bulges or hernias.

“With the addition of SenSura® Mio Convex Flip, we continue to build out our ostomy SenSura® Mio portfolio to meet more people’s needs. It is difficult to make a great fit for people with outward body profiles, but the curved, star-shaped barrier can do just that. We are confident that this will make a big difference to our users and give Coloplast a strong competitive edge,” says CEO Kristian Villumsen, Coloplast.

Committed to improving outcomes via quality products and life-long patient support
Ostomy care is the 2nd leading cause of 30-day readmission rates in the United States. Coloplast® Care, a comprehensive patient support program, provides patients with individualized support, education, and tools via a patient-focused advisor. The program has been shown to reduce 30-day readmission rates by 30 percent and ER visits by 45 percent.

“SenSura® Mio Convex Flip provides a new option for those living with an ostomy. By offering a new innovative product that supports the needs of more users, combined with the Coloplast Care program, we not only impact the quality of life for people living with a stoma – we also make a positive effect on health outcomes,” says Senior Vice President Manu Varma, Chronic Care in North America.

Coloplast is the global market leader in ostomy care products, holding 35-40% of the market. Ostomy care products experienced 8% organic growth in 2018, with double-digit growth coming from the United States.

Contacts
Lina Danstrup
Senior Media Relations Manager, Corporate Communications
+45 4911 2607
dklina@coloplast.com

Ellen Bjurgert
Vice President, Investor Relations
+45 49 11 33 76
dkebj@coloplast.com

Attachment

© OMX, source OMX

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on COLOPLAST
04/23COLOPLAST : Share buy-back week 16/2019
AQ
04/19BOSTON SCIENTIFIC : FDA orders surgical mesh manufacturers to stop selling and d..
AQ
04/19FDA orders companies to stop sale of pelvic surgical mesh in US
AQ
04/19BOSTON SCIENTIFIC : US regulator bans sale of transvaginal surgical mesh
AQ
04/18COLOPLAST : responds to FDA's decision to remove Surgical Transvaginal Mesh as T..
AQ
04/18COLOPLAST : Announcement no. 3/2019 - Coloplast responds to FDAs decision to rem..
AQ
04/18CORRECTION : Announcement no. 3/2019 - Coloplast responds to FDAs decision to re..
AQ
04/17BOSTON SCIENTIFIC : FDA takes action to protect women's health, orders manufactu..
AQ
04/17Coloplast responds to FDA's decision to remove Surgical Transvaginal Mesh as ..
GL
04/17CORRECTION : Announcement no. 3/2019 - Coloplast responds to FDA's decision to r..
AQ
More news
Financials (DKK)
Sales 2019 17 940 M
EBIT 2019 5 574 M
Net income 2019 4 224 M
Debt 2019 1 049 M
Yield 2019 2,48%
P/E ratio 2019 34,51
P/E ratio 2020 30,84
EV / Sales 2019 7,66x
EV / Sales 2020 7,06x
Capitalization 136 B
Chart COLOPLAST
Duration : Period :
Coloplast Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends COLOPLAST
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 18
Average target price 653  DKK
Spread / Average Target -5,3%
EPS Revisions
Managers
NameTitle
Lars Søren Rasmussen Chairman
Allan Rasmussen Executive Vice President-Global Operations
Anders Lonning-Skovgaard Chief Financial Officer & Executive Vice President
Oliver Johansen Senior VP-Global Research & Development
Niels Peter Louis-Hansen Deputy Chairman
Sector and Competitors
1st jan.Capitalization (M$)
COLOPLAST13.88%20 348
BECTON, DICKINSON AND COMPANY5.37%63 884
TELEFLEX INCORPORATED8.83%12 960
SHANDONG WEIGAO GROUP MEDICAL POLYMER CO20.28%4 404
HARTALEGA HOLDINGS BERHAD--.--%4 088
TOP GLOVE CORPORATION BERHAD--.--%2 987